summary: In this randomised trial the efficacy of IFNb-1b (Betaferon/Betaseron®) and glatiramer acetate (GA, Copaxone®) were compared. Seventy-five people with RRMS were included in the study. After a 2-year treatment period the authors found no differences between the 2 groups in terms of MRI activity (new lesions and enhancing lesions) and clinical activity (new relapses).

authors: Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD

source: Neurology. 2009 Mar 11

weblink: click here

category: Clinical Trials and Therapeutics

related research news: click here

glossary: